NL-OMON37098已完成4 期
Prospective, pharmacokinetic study for determination of the relationship between lean body weight and anti-Xa activity 4 hours after subcutaneous administration of 5700 IU nadroparin in morbidly obese patients after bariatric surgery. - Nadroparin and anti-Xa activity after bariatric surgery
Rijnstate Ziekenhuis0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •approval for Roux-en-Y gastric bypass
- •body weight of > 140 kg
排除标准
- •renal impairment (GFR < 30 and/or serum creatinin > 150)
- •Anticoagulation disorders (PT/APT > 2x norm)
- •Use of oral anticoagulation (such as acenocoumarol)
研究者
相似试验
进行中（未招募）
不适用
Profylaxis of venous thromboembolism after bariatric surgery.patientsperioperative in bariatric surgeryEUCTR2012-002816-19-NLRijnstate Hospital
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-000535-36-CZAbbott GmbH & Co. KG100
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-000535-36-DEAbbVie Deutschland GmbH & Co. KG100
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.Rheumatoid ArthritisEUCTR2012-000535-36-PLAbbott GmbH & Co. KG100
已完成
不适用
Clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhFVIII in previously treated patients with severe haemophilia ASevere haemophilia AHaematological DisordersHereditary factor VIII deficiencyISRCTN87293301Octapharma AG (Switzerland)20